Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Mesoblast limited    MSB   AU000000MSB8

MESOBLAST LIMITED (MSB)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
02/15/2018 02/16/2018 02/19/2018 02/20/2018 02/21/2018 Date
1.28(c) 1.25(c) 1.365(c) 1.36(c) 1.41 Last
761 284 911 024 1 090 511 712 630 1 886 277 Volume
+2.40% -2.34% +9.20% -0.37% +3.68% Change
More quotes
Financials ( AUD)
Sales 2018 42,9 M
EBIT 2018 -78,1 M
Net income 2018 -107 M
Finance 2018 26,4 M
Yield 2018 -
Sales 2019 63,5 M
EBIT 2019 -67,4 M
Net income 2019 -47,3 M
Debt 2019 5,44 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 14,4x
EV / Sales2019 10,3x
Capitalization 646 M
More Financials
Company
Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products.Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.The company was founded by Itescu Silviu on June 8, 2004 and... 
More about the company
Surperformance© ratings of Mesoblast limited
Trading Rating : Investor Rating :
More Ratings
Latest news on MESOBLAST LIMITED
01/11Mesoblast to Present at 36th Annual J.P. Morgan Healthcare Conference
GL
2017MESOBLAST : Receives FDA Regenerative Medicine Advanced Therapy Designation for ..
AQ
2017MESOBLAST : Mesoblasts Phase 3 Trial in Children With Acute Graft Versus Host Di..
AQ
2017Mesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for..
GL
2017MESOBLAST : Named Global Technology Leader in Cell Therapy Industry
AQ
2017Mesoblast’s Phase 3 Trial in Children With Acute Graft Versus Host Dise..
GL
2017MESOBLAST : grants TiGenix an exclusive global patent license to use adiposederi..
AQ
2017MESOBLAST LIMITED : Wired News – TiGenix Received an Exclusive Global Patent Lic..
AC
2017Tiny stem cell companies close in on major heart disease goals
RE
2017MESOBLAST : Named Global Technology Leader in Cell Therapy Industry
BU
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/152018 MPC-150-IM (rexlemestrocel-L; Mesoblast) Drug Analysis - : DUBLIN--(BUSI.. 
02/07It's almost time! is sitting down with former PM John Howard, Peter Ridd, ..
2
02/02Maxim Group Reaffirms “Buy” Rating for Mesoblast $MESO
1
01/31Maxim Group Thinks Mesoblast Ltd’s Stock is Going to Recover $MESO  
01/17Mesoblast $MESO Upgraded to “Buy” at Zacks Investment Research  
More tweets
Qtime:104
News from SeekingAlpha
01/12Where To Next? Tigenix Investors Have New Stem Cell Options 
01/12Mesoblast (MEOBF) Presents At 36th Annual J.P. Morgan Healthcare Conference -.. 
01/02OSIRIS THERAPEUTICS : Solutions To Challenging Problems 
2017YOUR DAILY PHARMA SCOOP : Aeterna Zentaris Gets FDA Nod, Valeant Finalizes Sprou.. 
2017Mesoblast receives RMAT designation from FDA for its cell therapy in heart fa.. 
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast limited Technical Analysis Chart | MSB | AU000000MSB8 | 4-Traders
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 3,29  AUD
Spread / Average Target 141%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Brian Jamieson Non-Executive Chairman
Paul Hodgkinson Chief Financial Officer
Donna L. Skerrett Chief Medical Officer
Paul Simmons Head-Research & New Product Development
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED-12.33%511
CELLTRION, INC.--.--%36 184
IQVIA HOLDINGS INC6.93%21 157
LONZA GROUP-7.82%18 346
INCYTE CORPORATION-6.91%18 156
NEKTAR THERAPEUTICS40.66%13 138